• 제목/요약/키워드: Immunotoxin

검색결과 11건 처리시간 0.021초

뇌종양세포주에서의 성장인자수용체의 발현 : 면역독소 치료의 연구를 위한 예비실험 (Growth Factor Receptor Expression on Brain Tumor Cell Lines : Preliminary Study for in vitro and in vivo Experiments of Immunotoxin Therapy)

  • 김기욱
    • Journal of Korean Neurosurgical Society
    • /
    • 제29권6호
    • /
    • pp.731-737
    • /
    • 2000
  • 목 적 : 종양세포의 세포면에서는 성장인자 수용체들이 과발현되고 이들이 성장인자들과 결합함으로서 세포의 성장을 촉진하게 된다. 원발성 악성 뇌종양에 대한 새로운 치료법 중 하나가 면역독소를 사용하는 방법이다. 독소는 대상 세포의 세포면에 있는 수용체를 통해 세포질로 이행되며, 면역독소가 선택적인 항종양작용을 나타내기 위해서는 수용체가 과발현되어야 한다. 강력한 세포독성의 효과가 있음에도 불구하고 면역독소를 환자에 투여하였을 때 종양을 완치시키지는 못하였는데, 면역독소의 효과에 영향을 미치는 여러 인자들에 대한 더 많은 연구가 요구된다. 이러한 연구에 사용되어질 뇌종양세포주들에서 성장인자수용체들의 발현 여부를 알아보기 위해 본 연구를 시행하였다. 대상 및 방법 : 한 개의 수모세포종 세포주(Daoy)와 두 개의 교모세포종 세포주(U373 MG, T98 G)에서, transferrin 수용체, insulin-like growth factor-1 수용체, 그리고 interleukin-4 수용체들의 발현을 flow cytometric analysis를 이용하여 조사하였다. 결 과 : Transferrin 수용체와 interleukin-4 수용체는 Daoy, U373 MG, 그리고 T98 G 모두에서 발현되었다. Insulin-like growth factor-1 수용체는 Daoy와 U373 MG에서는 발현되었지만 T98 G에서는 발현되지 않았다. 결 론 : Transferrin 수용체와 interleukin-4 수용체는 면역독소 치료에 적합한 것으로 보인다. 본 실험의 결과는 상기의 세포주를 사용하여 면역독소와 관련된 실험을 하는데 참고가 되어야하며, 면역독소 치료에 있어서 적절한 면역독소를 선택하는 문제 등 치료 모델을 확립하는데 고려되어야 할 것이다.

  • PDF

Stability and Cytotoxicity of Fab-Ricin A Immunotoxins Prepared with Water Soluble Long Chain Heterobifunctional Crosslinking Agents

  • Woo, Byung-Ho;Lee, Jung-Tae;Park, Myung-Ok;Lee, Kang-Ro;Han, Jeung-Whan;Park, Eun-Seok;Yoo, Sun-Dong;Lee, Kang-Choon
    • Archives of Pharmacal Research
    • /
    • 제22권5호
    • /
    • pp.459-463
    • /
    • 1999
  • The effects of the hindered and non-hindered water soluble long-chain disulfide bonds on the stability and cytotoxicity of the ricin A chain (RTA) immunotoxin were examined. The RTA immunotoxins were prepared with the Fab fragments of anti-common acute lymphoblastic leukemia antigen (CALLA) monoclonal antibody (Fab-RTA) using sulfosuccinimidyl-6-[(-methyl-(-2-pyridyldithio)toluamido]toluamido]hexanoate (S-LC-SMPT) and sulfosuccinimidyl-6-[3-(2-pyridyldithio-propionamido]hexanoate (S-LC-SPDP). The prepared Fab-RTA immunotoxins were evaluated for their conjugation yield, immunoreactivity, thermal and disulfide bond stability and cytotoxicity. The conjugation yield of the Fab-RTA immunotoxin from the water soluble long chain crosslinking agents, S-LC-SMPT and S-LC-SPDP, were comparable. Both Fab-RTA immunotoxins exhibited a similar immunoreactivity and thermal stability in aqueous solution. However, S-LC-SMPT -mediated Fab-RTA, sterically hindered, showed an enhanced disulfide bond stability in vitro over S-LC-SPDP mediated one. In the cytotoxicity against antigenic cell Daudi, the S-LC-SMPT -mediated RTA immunotoxin maintained a comparable cytotoxicity, compared with S-LC-SPDP mediated Fab-RTA immunotoxin.

  • PDF

섬자리공 유래 항바이러스 단백질과 항체 복합체를 이용한 HIV-1 감염세포의 선택적 제거 (Human Immunodeficiency Virus-Infected T Cells Are Selectively Killed by Monoclonal Anti-gp120 Antibody Coupled to Pokeweed Antiviral Protein)

  • 강미란;김윤구;홍효정;조명환;신형식;김선영
    • 대한바이러스학회지
    • /
    • 제28권4호
    • /
    • pp.383-391
    • /
    • 1998
  • A murine monoclonal antibody (mAb) specific for the envelope glycoprotein gp120 of human immunodeficiency virus type-I (HIV -1) was chemically coupled to pokeweed antiviral protein (PAP) from Phytolacca americana. The immunotoxin was purified by FPLC using S200 colum. The purified immunotoxin efficiently bound to HIV-infected T cells as evidenced by fluorescenceactivated cell sorter analysis. The immunotoxin selectively killed human T lymphoid lines infected with $HIV-1_{IIIB}$ at less than 250 pM of the immunotoxin cells, while PAP or mAb alone did not have any significant effect on infected cells. The uninfected control T cell lines were not affected. Human cells infected with HIV-2 or other HIV-1 strains were not killed, suggesting that the killing depends completely on the antibody used for coupling. These in vitro results suggest that the PAP-mAb conjugate may be used to selectively remove cells expressing viral antigens from individuals infected with HIV.

  • PDF

A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells

  • Lee, Sunju;Park, Sangsu;Nguyen, Minh Tan;Lee, Eunyoung;Kim, Julee;Baek, Sangki;Kim, Chong Jai;Jang, Yeon Jin;Choe, Han
    • BMB Reports
    • /
    • 제52권8호
    • /
    • pp.496-501
    • /
    • 2019
  • Conventionally, immunotoxins have been produced as a single polypeptide from fused genes of an antibody fragment and a toxin. In this study, we adopted a unique approach of chemical conjugation of a toxin protein and an antibody fragment. The two genes were separately expressed in Escherichia coli and purified to high levels of purity. The two purified proteins were conjugated using a chemical linker. The advantage of this approach is its ability to overcome the problem of low recombinant immunotoxin production observed in some immunotoxins. Another advantage is that various combinations of immunotoxins can be prepared with fewer efforts, because the chemical conjugation of components is relatively simpler than the processes involved in cloning, expression, and purification of multiple immunotoxins. As a proof of concept, the scFv of trastuzumab and the PE24 fragment of Pseudomonas exotoxin A were separately produced using E. coli and then chemically crosslinked. The new immunotoxin was tested on four breast cancer cell lines variably expressing HER2. The chemically crosslinked immunotoxin exhibited cytotoxicity in proportion to the expression level of HER2. In conclusion, the present study revealed an alternative method of generating an immunotoxin that could effectively reduce the viability of HER2-expressing breast cancer cells. These results suggest the effectiveness of this method of immunotoxin crosslinking as a suitable alternative for producing immunotoxins.

식물성 Toxin 류를 이용한 Immunotoxin 연구 (Immunotoxin using plant toxins for cancer theraphy)

  • 이강춘
    • 한국응용약물학회:학술대회논문집
    • /
    • 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
    • /
    • pp.210-210
    • /
    • 1994
  • 천연자원으로부터 얻어진 항암 또는 세포독성물질로는 주로 alkaloid, lignan, terpenoid, macrolide 등에 속하는 물질들이고 그 중 sesquiterpene lactone계열 화합물에서 세포독성 및 항종양 활성이 있는 물질이 다수 얻어졌으며 그 대부분은 국화과의 식물에서 분리 보고되고 있다. Achillea 속 식물은 국화과에 속하는 다년생초본으로 남한에는 톱풀과 산톱풀 2종만이 자생한다. screening 결과 이 두 식물에는 segquiterpene lactone 화합물과 Peroxide등 다수의 활성성분이 함유되어 있을 것으로 기대되어 본 연구에 착수하였다. 두 식물의 각 분획에 대하여 SNU-1(위암세포주)과 SNU-354(간암세포주)를 이용해 검색한 결과 두 식물 모두 MC ext.와 MeOH ext.에서 현저한 세포독성을 보였으며 현재 MC ext. 로부터 세포독성물질의 분리를 수행하고 있다. EtOAc ext.는 세포독성은 거의 나타내지 않았으나 flavonoid 성분이 다수 존재함을 확인하였으며 면역활성 및 enzyme inhibition등의 활성을 검토하고자 화합물을 분리하였다. 그 결과 톱풀로 부터는 luteolin-7-0-glucoside와 apigenin-7-0-glucoside를 그리고 산톱풀로부터는 luteolin-7-0-glucoside, apigenin-7-0-glucoside, luteolin, apigenin을 분리 확인 동정하였다.

  • PDF

Ricinus Communis로부터 분리된 ricin과 RCA의 독성 비교연구 (Toxic Activity of Ricin and RCA from Ricinus communis on Leukemia Cells and ICR Mice)

  • 김재호;장혜영
    • Toxicological Research
    • /
    • 제11권2호
    • /
    • pp.193-197
    • /
    • 1995
  • Antibody-toxin conjugates, termed immunotoxins, are currently being evaluated as potential new anticancer agents and one of the most extensively studied toxins for construction of immunotoxin is ricin which exists in the seeds of castor bean, Ricinus communis. Another toxic lectin from castor bean is RCA (Ricinus communis agglutinin). Both toxins are very homologous. We reported the puriffcation procedure and biological properties of ricin from the Korean castor bean in another place and here we report those of RCA. The purified RCA shows three bands on denatured SDS PAGE while ricin shows two bands. On cultured $K_{562}$ cells ricin and RCA both inhibit the multiplication of cells extensively. $30{\mu}g/ml$ of ricin shows 73% of inhibition rate at day 4 compared to 68% in same condition of RCA. The inhibition of multiplication of cells are directly proportional to the concentration of toxins and the incubation period. In every case ricin was more toxic than RCA. The $LD_{50}$ dose of ricin on ICR mice was 60 ng at day 3 but that of RCA was $10{\mu}g$.

  • PDF

Barley ribosome-inactivating protein의 결정화 및 X-선 실험

  • 서세원
    • 한국응용약물학회:학술대회논문집
    • /
    • 한국응용약물학회 1993년도 제2회 신약개발 연구발표회 초록집
    • /
    • pp.136-136
    • /
    • 1993
  • immunotoxin으로 쓰일 수 있는 리보솜 불활성화 단백질 (RIP, ribosome-inactivating protein)을 보리 씨앗에서 분리하였다 이 단백질은 분자량이 약 30,000 kDa 정도되고, pl가 9.0 보다 높다. 이러한 성질을 이용하여 Na-phosphate 완충용액으로 추출하고, 황산암모늄 60-80% 포화로 분획화하였다. 다음 CM-cellulose를 이용한 이온 교환 크로마토그래피, Sephacryl S-200 HR 컬럼을 이용한 gel filtration을 하여 순수히 분리하였고, 이를 전기영동하여 확인하였다.

  • PDF

A Divalent Immunotoxin Formed by the Disulfide Bond between Hinge Regions of Fab Domain

  • 최성혁;김지은;이용찬;장영주;최무현
    • Bulletin of the Korean Chemical Society
    • /
    • 제22권12호
    • /
    • pp.1361-1365
    • /
    • 2001
  • Recombinant immunotoxins are hybrid cytotoxic proteins designed to selectively kill cancer cells. A divalent immunotoxins, [B3(FabH1)-PE38]2, was constructed by recombining Fab domain of B3 antibody as a cell-targeting domain and Pseudo monas exotoxin A (PE) as a cytotoxic domain. Monoclonal antibody, B3, is the murine antibody (IgG1k) directed against Lewis Y-related carbohydrate antigens, which are abundant on the surface of many carcinomas. Fab fragment of this antibody was used in this study with the modified hinge sequence where last two cysteines out of three were mutated to serine. PE is a 66 kDa bacterial toxin that kills eukaryotic cells by inhibiting protein synthesis with ADP ribosylation of ribosomal elongation factor 2 (EF2). Fc region of B3 antibody was substituted with the truncated form of PE (38 kDa, PE38) on DNA level. [B3(FabH1)-PE38]2 was formed by disulfide bond between cysteines in the modified hinge region of B3(FabH1)-PE38. Each polypeptide for recombinant immunotoxins was overexpressed in Escherichia coli and collected as inclusion bodies. Each inclusion body was solubilized and refolded, and cytotoxic effects were measured. Divalent immunotoxins, [B3(FabH1)-PE38]2, had ID50 values of about 10 ng/mL on A431 cell lines and about 4 ng/mL on CRL1739 cell lines. Control immunotoxins, B3(scFv)-PE40, had ID50 values of about 28 ng/mL on A431 cell lines and about 41 ng/mL on CRL1739 cell lines. Divalent immunotoxins, [B3(FabH1)-PE38]2, had higher cytotoxic effects than B3(scFv)-PE40 control immunotoxins.

Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines

  • Hajighasemlou, Saieh;Alebouyeh, Mahmoud;Rastegar, Hossein;Manzari, Mojgan Taghizadeh;Mirmoghtadaei, Milad;Moayedi, Behjat;Ahmadzadeh, Maryam;Parvizpour, Farzad;Johari, Behrooz;Naeini, Maria Moslemi;Farajollahi, Mohammad M
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권14호
    • /
    • pp.5977-5981
    • /
    • 2015
  • Background: Worldwide, breast cancer is the most common cancer diagnosed among women and a leading cause of cancer deaths. The age of onset in Iran has become reduced by a decade for unknown reasons. Herceptin, a humanized monoclonal antibody, is a target therapy for breast cancer cells with over expression of HER2-neu receptors, but it is an expensive drug with only 20% beneficial rate of survival. This study introduces a novel approach to enhance the efficacy of this drug through immunoconjugation of the antibody to botulinum toxin. Decreasing the cost and adverse effects of the antibody were secondary goals of this study. Materials and Methods: Botulinum toxin was conjugated with Herceptin using heterobifunctional cross linkers, succinimidyl acetylthiopropionate (SATP) and sulfo-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) according to the supplier's guidelines and tested on two breast cancer cell lines: SK-BR-3 and BT-474. Toxin and Herceptin were also used separately as controls. The cytotoxicity assay was also performed using the new bioconjugate on cultured cells with Alamar blue and a fluorescence plate reader. Results: Herceptin-Toxin bioconjugation significantly improved Herceptin efficacy on both breast cancer cell lines when compared to the control group. Conclusions: Toxin-Herceptin bioconjugation can be a potential candidate with increased efficiency for treating breast cancer patients with over expression of the HER2 receptor.

Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics

  • Minh Quan Nguyen;Do Hyung Kim;Hye Ji Shim;Huynh Kim Khanh Ta;Thi Luong Vu;Thi Kieu Oanh Nguyen;Jung Chae Lim;Han Choe
    • Molecules and Cells
    • /
    • 제46권12호
    • /
    • pp.764-777
    • /
    • 2023
  • Recombinant immunotoxins (RITs) are fusion proteins consisting of a targeting domain linked to a toxin, offering a highly specific therapeutic strategy for cancer treatment. In this study, we engineered and characterized RITs aimed at mesothelin, a cell surface glycoprotein overexpressed in various malignancies. Through an extensive screening of a large nanobody library, four mesothelin-specific nanobodies were selected and genetically fused to a truncated Pseudomonas exotoxin (PE24B). Various optimizations, including the incorporation of furin cleavage sites, maltose-binding protein tags, and tobacco etch virus protease cleavage sites, were implemented to improve protein expression, solubility, and purification. The RITs were successfully overexpressed in Escherichia coli, achieving high solubility and purity post-purification. In vitro cytotoxicity assays on gastric carcinoma cell lines NCI-N87 and AGS revealed that Meso(Nb2)-PE24B demonstrated the highest cytotoxic efficacy, warranting further characterization. This RIT also displayed selective binding to human and monkey mesothelins but not to mouse mesothelin. The competitive binding assays between different RIT constructs revealed significant alterations in IC50 values, emphasizing the importance of nanobody specificity. Finally, a modification in the endoplasmic reticulum retention signal at the C-terminus further augmented its cytotoxic activity. Our findings offer valuable insights into the design and optimization of RITs, showcasing the potential of Meso(Nb2)-PE24B as a promising therapeutic candidate for targeted cancer treatment.